AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15299060 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of CBF
Number of subjects: 10
Study 10665516 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% t.i.d.
Number of subjects: 0
Study 10665516 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2.0% t.i.d.
Number of subjects: 0
Study 9354317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedisamil (100 mg twice daily)
Number of subjects: 0
Study 9354317 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg twice daily)
Number of subjects: 0
Study 9354317 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tedisamil and Atenolol
Number of subjects: 0
Study 9354317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedisamil alone
Number of subjects: 0
Study 9354317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedisamil alone and in combination with Atenolol
Number of subjects: 0
Study 8308936 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg t.i.d.
Number of subjects: 56
Study 8308936 — intervention group
Group type: COMPARATOR
Intervention: Placebo 10 mg t.i.d.
Number of subjects: 56
Study 2952125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 0
Study 2952125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31620778 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1905
Study 31620778 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1905
Study 29725790 — intervention group
Group type: EXPERIMENTAL
Intervention: Active, Linkage, Engagement, Retention and Treatment (ALERT) specialist for outreach and health coaching
Number of subjects: 116
Study 29725790 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 116
Study 26365587 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% citrate anticoagulation
Number of subjects: 37
Study 26365587 — intervention group
Group type: COMPARATOR
Intervention: 15% citrate anticoagulation
Number of subjects: 37
Study 24781720 — intervention group
Group type: EXPERIMENTAL
Intervention: Recumbent cycling exercise during dialysis
Number of subjects: 65
Study 24781720 — intervention group
Group type: COMPARATOR
Intervention: Simple stretching exercises (Control)
Number of subjects: 65
Study 22947269 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment supported by self‐monitoring (pro‐active counseling, pedometer, weighing scale, blood pressure device)
Number of subjects: 179
Study 22947269 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without self‐monitoring
Number of subjects: 179
Study 22947269 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment supported by self‐monitoring
Number of subjects: 179
Study 20369524 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flex prosthesis (HF group)
Number of subjects: 58
Study 20369524 — intervention group
Group type: COMPARATOR
Intervention: Conventional posterior-stabilized prosthesis (PS group)
Number of subjects: 58
Study 18302810 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 1 mg
Number of subjects: 17
Study 18302810 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 0.5 mg
Number of subjects: 17
Study 18302810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 15546895 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access group
Number of subjects: 209
Study 15546895 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 209
Study 12463319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX group, n = 15)
Number of subjects: 30
Study 12463319 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 30
Study 10348579 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive abciximab
Number of subjects: 20
Study 10348579 — intervention group
Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 20
Study 7569458 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg od plus amoxicillin 500 mg tid (group A)
Number of subjects: 80
Study 7569458 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate 260 mg bid, metronidazole 250 mg tid and amoxicillin 500 mg tid (group B)
Number of subjects: 80
Study 1943411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric parenteral nutrition
Number of subjects: 0
Study 1943411 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric parenteral nutrition
Number of subjects: 0
Study 7026255 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (1 mg/kg body weight)
Number of subjects: 12
Study 7026255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 12
Study 31196765 — intervention group
Group type: EXPERIMENTAL
Intervention: TR‐RPDs
Number of subjects: 28
Study 30664267 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF), 12 doses of 300 μg each in 28 days
Number of subjects: 33
Study 30664267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30664267 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 33
Study 28508697 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical estrogen (GI)
Number of subjects: 30
Study 28508697 — intervention group
Group type: COMPARATOR
Intervention: Topical genistein (GII)
Number of subjects: 30
Study 26422051 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (300 min/week at lactate threshold)
Number of subjects: 81
Study 26422051 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintain usual lifestyle)
Number of subjects: 81
Study 26422051 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 81
Study 24139829 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous allergen immunotherapy (SCIT)
Number of subjects: 44
Study 24139829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual allergen immunotherapy (SLIT)
Number of subjects: 44
Study 24139829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22080312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodypump® training (n = 9)
Number of subjects: 19
Study 19121220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity self-management lifestyle intervention
Number of subjects: 250
Study 19121220 — intervention group
Group type: COMPARATOR
Intervention: Standard education (control)
Number of subjects: 250
Study 17537205 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm gold tip catheter
Number of subjects: 60
Study 17537205 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally irrigated-tip catheter
Number of subjects: 60
Study 17537205 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm platinum-iridium tip catheter
Number of subjects: 60
Study 15072897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 930
Study 15072897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study 11287024 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block with conscious sedation
Number of subjects: 150
Study 11287024 — intervention group
Group type: COMPARATOR
Intervention: Paracervical block only (control group)
Number of subjects: 150
Study 11287024 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block with and without conscious sedation
Number of subjects: 150
Study 9250791 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis for opportunistic infections including immunoglobulin (3.5 months), pyrimethamine-sulfadiazine (4 months), fluconazole (2.5 months), cotrimoxazole or pentamidine (2 years), penicillin (lifelong), and dietary precautions (4 months).
Number of subjects: 7
Study 9250791 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis for opportunistic infections developed on an ongoing basis as new infectious complications were seen.
Number of subjects: 7
Study 8510706 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.33 mg/kg) administered orally every eight hours during febrile illnesses
Number of subjects: 406
Study 8510706 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally every eight hours during febrile illnesses
Number of subjects: 406
Study 8510706 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (in children who had seizures while receiving the medication)
Number of subjects: 406
Study 8510706 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (among children who took at least one dose)
Number of subjects: 406
Study 3499163 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted overnight
Number of subjects: 12
Study 3499163 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial
Number of subjects: 12
Study 3499163 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and 15 ml aluminium hydroxide gel
Number of subjects: 12
Study 3499163 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial and 15 ml aluminium hydroxide gel
Number of subjects: 12
Study 3499163 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and 15 ml aluminium and magnesium hydroxide gel
Number of subjects: 12
Study 3499163 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial and 15 ml aluminium and magnesium hydroxide gel
Number of subjects: 12
Study 31446143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 180
Study 31446143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 28342633 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 test (PCA3 ≥35)
Number of subjects: 5199
Study 28342633 — intervention group
Group type: COMPARATOR
Intervention: Observation (PCA3 <35)
Number of subjects: 5199
Study 28342633 — intervention group
Group type: COMPARATOR
Intervention: ERSPC RC‐3
Number of subjects: 5199
Study 28342633 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3-35 to avoid IBx
Number of subjects: 5199
Study 26289996 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 23
Study 26289996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23374879 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise without a clear treatment rationale
Number of subjects: 500
Study 23374879 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise with treatment rationale
Number of subjects: 500
Study 23374879 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural activation with treatment rationale
Number of subjects: 500
Study 23374879 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural activation without a clear treatment rationale
Number of subjects: 500
Study 23374879 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group with delayed treatment
Number of subjects: 500
Study 23374879 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (including relapse prevention program)
Number of subjects: 500
Study 20602868 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal free healthy breakfast provision in intervention schools
Number of subjects: 4472
Study 19325484 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antifungal therapy
Number of subjects: 0
Study 19325484 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 0
Study 17543895 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic methylphenidate (MPH) 0.3 mg/kg/dose
Number of subjects: 75
Study 17543895 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic methylphenidate (MPH) 0.6 mg/kg/dose
Number of subjects: 75
Study 17543895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 15547635 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 21
Study 15547635 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa with exercise
Number of subjects: 21
Study 15547635 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa without exercise
Number of subjects: 21
Study 11969276 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary heart disease risk factors in men
Number of subjects: 12000
Study 11969276 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary heart disease risk factors in women
Number of subjects: 12000
Study 11969276 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-attributable risks in men
Number of subjects: 12000
Study 11969276 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-attributable risks in women
Number of subjects: 12000
Study 9788403 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I (583 patients)
Number of subjects: 1547
Study 9788403 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II (667 patients)
Number of subjects: 1547
Study 9788403 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III (249 patients)
Number of subjects: 1547
Study 9788403 — intervention group
Group type: EXPERIMENTAL
Intervention: Class IV (48 patients)
Number of subjects: 1547
Study 8004358 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7 g 3‐sn‐polyenylphosphatidylcholine (PPC) daily, orally for 2 months
Number of subjects: 30
Study 8004358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2682593 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline (AMI)
Number of subjects: 12
Study 2682593 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Org 3770 (ORG)
Number of subjects: 12
Study 2682593 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg diazepam (DZ)
Number of subjects: 12
Study 2682593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AMI and DZ
Number of subjects: 12
Study 2682593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ORG and DZ
Number of subjects: 12
Study 2682593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29948573 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-out healthcare surveys with varying questionnaire lengths (48-127 items)
Number of subjects: 0
Study 28973076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin dietary supplementation (2 daily capsules) for 6 months
Number of subjects: 120
Study 28973076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26173631 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg
Number of subjects: 1463
Study 26173631 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg
Number of subjects: 1463
Study 26173631 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg
Number of subjects: 1463
Study 26173631 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 100 mg
Number of subjects: 1463
Study 23303873 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐GOS (galactooligosaccharide mixture)
Number of subjects: 45
Study 21112898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT-ON)
Number of subjects: 262
Study 21112898 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Therapy (CRT-OFF)
Number of subjects: 262
Study 18956206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalometric analysis using radiographs
Number of subjects: 28
Study 18956206 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniofacial computed tomography (CT)
Number of subjects: 28
Study 18956206 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 17118507 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial toothbrush with triclosan
Number of subjects: 10
Study 17118507 — intervention group
Group type: COMPARATOR
Intervention: Regular toothbrush
Number of subjects: 10
Study 17118507 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial toothbrush with toothpaste
Number of subjects: 10
Study 17118507 — intervention group
Group type: COMPARATOR
Intervention: Regular toothbrush with toothpaste
Number of subjects: 10
Study 17118507 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial toothbrush without toothpaste
Number of subjects: 10
Study 17118507 — intervention group
Group type: COMPARATOR
Intervention: Regular toothbrush without toothpaste
Number of subjects: 10
Study 17118507 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial toothbrush
Number of subjects: 10
Study 15078238 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patch (AP, 15 mg daily, n = 100)
Number of subjects: 200
Study 15078238 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (PP, n = 100)
Number of subjects: 200
Study 11259927 — intervention group
Group type: EXPERIMENTAL
Intervention: Becaplermin
Number of subjects: 0
Study 11259927 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9271009 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR overexpression in laryngeal SCC (n = 20; 83%)
Number of subjects: 24
Study 9271009 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic laryngeal SCC (N = 5)
Number of subjects: 24
Study 9271009 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal carcinoma cases with EGFR overexpression
Number of subjects: 24
Study 9271009 — intervention group
Group type: COMPARATOR
Intervention: Vocal cord polyps
Number of subjects: 24
Study 7509371 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal pregnancy message
Number of subjects: 100
Study 7509371 — intervention group
Group type: COMPARATOR
Intervention: Subliminal penetration message
Number of subjects: 100
Study 7509371 — intervention group
Group type: COMPARATOR
Intervention: Supraliminal pregnancy message
Number of subjects: 100
Study 7509371 — intervention group
Group type: COMPARATOR
Intervention: Supraliminal penetration message
Number of subjects: 100
Study 2691481 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate (Augmentin)
Number of subjects: 0
Study 2691481 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin
Number of subjects: 0
Study 235835 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 20
Study 235835 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 20
Study 235835 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation
Number of subjects: 20
Study 235835 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologic improvement
Number of subjects: 20
Study 31290404 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-delivered growth mindset intervention plus smoking cessation app
Number of subjects: 398
Study 31290404 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation app alone
Number of subjects: 398
Study 28459069 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate hemodialysis (BHD)
Number of subjects: 10
Study 28459069 — intervention group
Group type: EXPERIMENTAL
Intervention: Online hemodiafiltration (HDF)
Number of subjects: 10
Study 28459069 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 10
Study 25410416 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress procedure
Number of subjects: 40
Study 25410416 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 40
Study 24078934 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 120
Study 24078934 — intervention group
Group type: COMPARATOR
Intervention: Other positions (supine and right lateral)
Number of subjects: 120
Study 16966390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg/kg) plus midazolam (0.1 mg/kg; max: 2.5 mg)
Number of subjects: 102
Study 16966390 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (50%)/oxygen (50%) plus hematoma block (2.5 mg/kg of 1% buffered lidocaine)
Number of subjects: 102
Study 15259923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammogram for women with painful breasts
Number of subjects: 726
Study 15259923 — intervention group
Group type: COMPARATOR
Intervention: Control group mammogram
Number of subjects: 726
Study 10717781 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected intercourse
Number of subjects: 12
Study 10717781 — intervention group
Group type: COMPARATOR
Intervention: Intact condoms
Number of subjects: 12
Study 10717781 — intervention group
Group type: EXPERIMENTAL
Intervention: Punctured condoms
Number of subjects: 12
Study 10717781 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed condoms
Number of subjects: 12
Study 7546527 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hemodiafiltration
Number of subjects: 87
Study 7546527 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysis
Number of subjects: 87
Study 1743624 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOEP (cyclophosphamide 750 mg/m2 iv d 1, doxorubicin 50 mg/m2 iv d 1, vincristine 2 mg iv d 1, etoposide 100 mg/m2 iv d 3‐5, prednisolone 100 mg po d 1‐5)
Number of subjects: 146
Study 1743624 — intervention group
Group type: COMPARATOR
Intervention: hCHOP alternating with IVEP (cyclophosphamide 1200 mg/m2 iv d 1, doxorubicin 40 mg/m2 iv d 1 + 2, vincristine 2 mg iv d 1, prednisolone 100 mg po d 1‐5; ifosfamide 1500 mg/m2 iv d 1‐5, vindesine 3 mg/m2 iv d 1, etoposide 120 mg/m2 iv d 3‐5, prednisolone 100 mg po d 1‐5)
Number of subjects: 146
Study 1743624 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 146
Study 1743624 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 146
Study 7075652 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg orally
Number of subjects: 6
Study 30852696 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS on the unaffected hemisphere and physiotherapy (PT)
Number of subjects: 20
Study 30852696 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation and physiotherapy (PT)
Number of subjects: 20
Study 28467363 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet + EVOO
Number of subjects: 5802
Study 28467363 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet + Nuts
Number of subjects: 5802
Study 28467363 — intervention group
Group type: COMPARATOR
Intervention: Control (low-fat diet)
Number of subjects: 5802